ARCHIVES

Research vs. Delivery? Advisors Debate NCI Role In Review of Community Program.

This article is from The Cancer Letter archive.

Vol. 34 No. 43 | November 21, 2008

Download PDF Visit The Full Archive

Related Articles

NCI Closes Iressa Trial For NSCLC When Data Indicate No Survival Benefit

April 29, 2005

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

July 21, 2006

Volasertib Shows Response In 31 Percent of Acute Myeloid Leukemia Patients

December 28, 2012

FDA Invites Ad Hoc Consumer Reps To ODAC Meetings

February 17, 1995

RFAs: Patient Outcomes “5-A-Day” Program

April 10, 1992

Spectral Mammography “Like Color vs. Black & White TV”

August 31, 2012